Wire · opportunities
AstraZeneca scores in lung cancer; Sandoz inks a China deal
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 August 2026 · Fusion42 review
AstraZeneca's Tagrisso combined with Hutchmed’s Orpathys has extended survival for certain lung cancer patients, marking a significant clinical advancement. Additionally, Sandoz secured a strategic deal in China, highlighting growing pharma collaborations in the region.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Biotech founders working on lung cancer should target partnerships that blend novel and existing therapies like AstraZeneca’s approach, as China’s pharma market opens more deal-making pathways. Sandoz's moves reveal growing appetite for local collaborations that you can now pursue.
◆ Coverage
1 source · 18 Aug 2026
◆ Related on Wire
◆ Topics